SY-1365

SY-1365 (Mevociclib) is a selective covalent CDK7 inhibitor. SY-1365 inhibited cell growth of many different cancer types at nanomolar concentrations. SY-1365 treatment decreased MCL1 protein levels, and cancer cells with low BCL-XL expression were found to be more sensitive to SY-1365. SY-1365 demonstrated substantial anti-tumor effects in multiple AML xenograft models as a single agent. SY-1365-induced growth inhibition was enhanced in combination with the BCL2 inhibitor venetoclax.


Cat. No.: EX-A3114	Purity: >98%

	Chemical structure of SY-1365

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
50mg	790	In-stock
100mg	1500	In-stock
250mg	2400	In-stock
500mg	Get quote	In-stock
1g	Get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Mevociclib
CAS No.	1816989-16-8
Purity	>98%
Formula	C31H35ClN8O2
Mol Weight	587.115
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7. Hu S, et al. Cancer Res. 2019 Jul 1;79(13):3479-3491. PMID: 31064851.
CoA	CoA of SY-1365

Smiles:	O=C(C1=NC=C(NC(/C=C/CN(C)C)=O)C=C1)N[C@@]2(C)CCC[C@@H](NC3=NC=C(Cl)C(C4=CNC5=C4C=CC=C5)=N3)C2


		Search